117th Congress · HOUSE BILLBILL

H.R. 4278 — To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.

“To direct the Comptroller General of the United States to conduct a study on how direct-to-consumer pharmaceutical advertising negatively impacts drug costs to consumers, and for other purposes.”

Health

Introduced Jun 30, 2021

Last action Jul 1, 2021

Pipeline · Bill → Law

Step 1

Introduced

Jun 30, 2021

Step 2

Referred

Jul 1, 2021

E&C

Step 3

Committee

Step 4

House floor

Step 5

Senate

Step 6

Resolve Changes

Step 7

Signed

SummaryNo summary available

No CRS summary available for this bill.

Provisions · 1 sectionsIntroduced in House

Timeline · 3 actions

Jul 1, 2021

Referred to the Subcommittee on Health.

Jun 30, 2021

Introduced in House

Jun 30, 2021

Referred to the House Committee on Energy and Commerce.